Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for SciSparc Ltd. (SPRC : NSDQ)

• Company Description    SciSparc Ltd. is a specialty clinical-stage pharmaceutical company. It focuses on the development of therapies to treat disorders of the central nervous system. The company's product pipeline includes SCI-110, SCI-160 and SCI-210. SciSparc Ltd. is based in TEL AVIV, Israel. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $6.91 Daily Weekly Monthly 20 Day Moving Average: 11,931 shares Shares Outstanding: 0.53 (millions) Market Capitalization: $3.69 (millions) Beta: 0.72 52 Week High: $27.51 52 Week Low: $4.14 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.39% -2.40% 12 Week 16.39% -2.10% Year To Date -8.63% -14.44%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20 RAUL WALLENBERG STREET TOWER A 2ND FLOOR - TEL AVIV,L3 6971916 ISR ph: 972-3717-5777 fax: - ir@scisparc.com http://www.scisparc.com

• General Corporate Information    Officers Oz Adler - Chief Executive Officer and Chief Financial Office Amitay Weiss - Chairman Itschak Shrem - President and Director Amnon Ben Shay - Director Alon Dayan - Director Peer Information SciSparc Ltd. (GSAC) SciSparc Ltd. (CASI) SciSparc Ltd. (ALCD.) SciSparc Ltd. (OMNN) SciSparc Ltd. (CGPI.) SciSparc Ltd. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: M82618121 SIC: 5500 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 0.53 Most Recent Split Date: 7.00 (0.05:1) Beta: 0.72 Market Capitalization: $3.69 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.38 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 5.36 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 5.28 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -573.20 Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 18.13 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - 3.03 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©